MedTrace Logo

Evaluation of the Effects of Chinese Medical Treatment on Leucopenia After Chemotherapy in Breast Cancer Patients

NCT01359501 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2012-10-23

No results posted yet for this study

Summary

This is a two-year double blind, placebo-controlled, and randomized clinical trial, which is aimed to evaluate the effects of Chinese medical treatment on leucopenia after chemotherapy in breast cancer patients.

Conditions

Interventions

DRUG

Chinese medical treatment-LCH1

Start to take the powder of Chinese herb-LCH1 3g\*BID just after the 1st chemotherapy, and Stop 2-3 weeks after the final cycle of chemotherapy.

DRUG

Placebo

Start to take the powder of Placebo 3g\*BID just after the 1st chemotherapy, and stop 2-3 weeks after the final chemotherapy.

Sponsors & Collaborators

  • Department of Health, Executive Yuan, R.O.C. (Taiwan)

    collaborator OTHER_GOV

  • China Medical University Hospital

    lead OTHER

Principal Investigators

  • Hwei-Chung Wang, MD. · Devision of Breast Surgery, China Medical University Hospital

  • Yi-Chang Su, MD., PhD. · School of Chinese Medicine, China Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01359501 on ClinicalTrials.gov